Richard Gonzalez compensation by year
AbbVie Summary Compensation Table · all 9 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $1,600,000 | $1,638,462 | $1,650,000 | $1,650,000 | $1,688,462 | $1,700,000 | $1,700,000 | $1,700,000 | $1,603,846 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $9,318,854 | $9,606,360 | $11,509,090 | $8,887,088 | $11,644,996 | $12,573,689 | $15,301,308 | $13,701,890 | $14,998,650 |
| Option awards | $2,360,323 | $2,559,270 | $2,760,764 | $2,246,253 | $2,781,662 | $3,134,649 | $3,598,419 | $3,437,871 | $3,577,772 |
| Non-equity incentive | $3,600,000 | $4,331,250 | $3,898,125 | $4,335,000 | $4,908,750 | $4,908,750 | $3,927,000 | $3,500,000 | $4,414,500 |
| Pension and deferred compensation | $3,232,531 | $3,496,704 | $463,205 | $3,366,720 | $2,224,135 | $780,993 | $439,214 | $1,331,617 | $1,863,298 |
| All other | $859,216 | $993,197 | $990,685 | $1,125,537 | $759,586 | $814,073 | $1,321,244 | $1,990,594 | $2,044,822 |
| Total | $20,970,924 | $22,625,243 | $21,271,869 | $21,610,598 | $24,007,591 | $23,912,154 | $26,287,185 | $25,661,972 | $28,502,888 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AbbVie Inc. DEF 14A filed March 24, 2025, accession 0001558370-25-003537, and prior-year filings. Open the filing on EDGAR.
How this page was built: the AbbVie Inc. filed document, accession 0001558370-25-003537. Every figure is read from that document and cited to the page and table it appears in. Filed March 24, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 82,154 | $14,598,766 | — |
| PSU | 75,746 | $13,460,064 | — |
| PSU | 66,417 | $11,802,301 | — |
| Option | 52,539 | — | $144.54 |
| Option | 76,524 | — | $149.62 |
| Option | 113,472 | — | $175.28 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AbbVie Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2024 proxy (filed March 24, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-03-31 | Gift | — | 2,450 | $0.00 | 386,479 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
AbbVie’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Robert Michael | Chairman of the Board and Chief Executive Officer | $32,530,984 |
| Jeffrey Stewart | Executive Vice President, Chief Commercial Officer | $15,435,304 |
| Scott Reents | Executive Vice President, Chief Financial Officer | $12,353,002 |
| Azita Saleki-Gerhardt | Executive Vice President, Chief Operations Officer | $10,791,976 |
| Roopal Thakkar | Executive Vice President, Research & Development and Chief Scientific Officer | $9,912,843 |
Board service
AbbVie board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $0 | $10,365,982 | $2,499,343 | $2,484,243 | $17,071,423 |
| FY2024 | $0 | $0 | $0 | $0 | — |
| FY2023 | $0 | $0 | $0 | $0 | — |
| FY2022 | — | — | — | — | — |
| FY2021 | — | — | — | — | — |
Each year as the company reported it in AbbVie's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: AbbVie pays directors a $125,000 cash retainer and $225,000 in Restricted Stock Units. As stated in AbbVie's FY2025 proxy.
Richard Gonzalez's compensation dossier, AbbVie
You have read Richard Gonzalez's totals and holdings. The dossier adds each equity grant AbbVie disclosed for Richard Gonzalez and AbbVie's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full AbbVie compensation record
free company briefThis page is one person within AbbVie's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the AbbVie proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order AbbVie's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AbbVie's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ABBV
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.